From Medscape Gastroenterology

Coverage from the

European Association for the Study of the Liver (EASL) Congress 2024

June 05 - 08, 2024; Milan, Italy & Online

June 05 - 08, 2024 Milan, Italy & Online

Conference News

EASL Congress 2024 Significant Benefit With Liver Transplantation in ACLF
Medscape Medical News, June 13, 2024
EASL Congress 2024 'Dramatic' Phase 2 Results for Survodutide in MASH, Fibrosis
Medscape Medical News, June 12, 2024
EASL Congress 2024 Seladelpar Shows Clinically Meaningful Improvements in PBC
Medscape Medical News, June 11, 2024

EASL Congress 2024 Tirzepatide Shows Improvements in MASH Resolution, Fibrosis
Medscape Medical News, June 10, 2024
EASL Congress 2024 iLFT Platform Helps Detect Chronic Liver Disease
Medscape Medical News, June 7, 2024
EASL Congress 2024 FMT Could Prevent Hepatic Encephalopathy in Cirrhosis
Medscape Medical News, June 6, 2024

Medscape Gastroenterology©

Popular News From ILC 2023

'Exciting Time for NASH' With Resmetirom Phase 3 Results The 52-week results of the phase 3 MAESTRO-NASH trial show promise for resmetirom. One expert called the trial results a 'real game-changer in the field of fatty liver disease'.
Medscape Medical News, Jun 22, 2023
Pegozafermin Improves Fibrosis in NASH in Phase 2b Study In the phase 2b ENLIVEN trial, the investigational drug pegozafermin met both primary endpoints at 24 weeks and led to improvements in fibrosis, paving the way for phase 3 development.
Medscape Medical News, Jun 28, 2023
FMT Modifies Gut Microbiome, Reduces Ammonia in Cirrhosis Fecal microbiota transplant (FMT) promotes restoration of the gut microbiota, enzymes, and immune responses, and reduces ammonia build-up in patients with cirrhosis, a pilot study found.
Medscape Medical News, Jun 23, 2023

Previous Coverage

Related Resources

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC. This website also contains material copyrighted by 3rd parties.